CFTR and cystic fibrosis: In August 2020, a triple combination of CFTR modulators, containing elexacaftor, tezacaftor, and ivacaftor (ETI), was licensed in the EU to treat people living with cystic fibrosis (pwCF) with at least one F508del mutation.